Evaxion Converts Debt to Equity in EIB Agreement

The latest update is out from Evaxion Biotech ( (EVAX) ).

On July 11, 2025, Evaxion A/S finalized an agreement with the European Investment Bank (EIB) to convert €3.5 million of its €7 million loan into equity. This move enhances Evaxion’s equity by $4.1 million, reduces liabilities, simplifies the balance sheet, and improves financial flexibility and cash flow. The agreement, which involves EIB purchasing Evaxion warrants at a premium, is expected to positively impact the company’s financial management and stakeholder confidence.

The most recent analyst rating on (EVAX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.

Spark’s Take on EVAX Stock

According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.

Evaxion Biotech’s overall score is driven by its significant revenue growth and positive earnings call outlook, with notable R&D achievements and partnerships. However, financial instability and negative profitability significantly weigh down the score. Technical indicators show some short-term momentum, yet valuation remains a concern due to the lack of profitability and dividends.

To see Spark’s full report on EVAX stock, click here.

More about Evaxion Biotech

Evaxion A/S is a clinical-stage TechBio company based in Denmark, specializing in the development of AI-Immunology™ powered vaccines. The company utilizes its proprietary AI platform to create novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline and a preclinical infectious disease pipeline, aiming to provide innovative treatment options for high unmet medical needs.

Average Trading Volume: 96,609

Technical Sentiment Signal: Sell

Current Market Cap: $3.56M

Learn more about EVAX stock on TipRanks’ Stock Analysis page.